In a paper published by Yongpisarn et al in Frontiers in Medicine, researchers endeavored to evaluate the prevalence of patients with psoriasis who are at high or low risk for advanced liver fibrosis, and additionally, to determine the risk factors for developing liver fibrosis. After performing a systematic review and meta-analysis using multiple literature databases, the researchers found 9.66% of the total population with psoriasis is at high risk for advanced liver fibrosis; while 77.79% of the population is at low risk, researchers added that the remaining 22.21% of patients require further testing. Risk factors for the development of liver fibrosis include age 50 years and older, as well as comorbidities such as obesity, diabetes mellitus, hypertension, dyslipidemia, and/or metabolic syndrome. Regarding next steps in this research, the study authors concluded, “Further research is required to determine why the prevalence of patients at high risk for advanced liver fibrosis is higher in European countries, the performance of noninvasive tests for the detection of advanced liver fibrosis in patients with psoriasis, and the extent of association between methotrexate use, particularly its cumulative dose, and liver fibrosis.”